Syngene International Limited’s Post

Hurry! ⏰ If you are in and around #Copenhagen in September, join us at BioInnovation Institute for this exciting in-person event. Syngene is excited to host "Nordics Discovery", our inaugural scientific symposium, or as we like to call it, Syn-posium, in Europe, on preclinical research in the drug discovery space. The symposium will feature insights from our drug discovery experts Ralf Guenther and Miquel Salvà, who will discuss the latest advancements, strategies, and challenges in preclinical research. Whether you are a student, a postdoc, a faculty member, or a professional in the biotech or pharma sector, this symposium will offer you valuable insights and opportunities to advance your research. Don't miss this unique opportunity to join the focused preclinical research community. 👉 Register now! Note: This is an in-person event with limited seats. #NordicsDiscovery #DrugDiscovery #PreclinicalResearch #SyngeneSynposium #SyngeneDrugDiscovery

📌 We are excited to attend the ISSX/JSSX 2024 conference from September 15-18, 2024 at Hilton Hawaiian Village Waikiki Beach Resort, Honolulu, Hawaii. Meet our Head of DMPK, Dr. Vishwottam Kandikere to discuss how Syngene can help you troubleshoot and accelerate your drug discovery and development programs.   Syngene offers a comprehensive suite of DMPK studies across the modalities, including in vitro ADME and in vivo Pharmacokinetics (PK) studies spanning discovery and early development phases. Our capabilities include developing high-quality, customized assays across a range of protocols powered by dual engine one at Bangalore and second one at Hyderabad labs.   Coupled with state-of-the-art infrastructure, we also offer expertise in antibody therapeutics. Our expertise spans therapeutic mAb discovery, reagent and tool antibody generation, critical reagent generation, large-scale protein expression, and purification of various formats of antibodies.   Our services include generating CAR-T/TCR and related in vitro assays; assay-based characterization of mAbs; bispecific; nanobodies (binding and cytotoxicity); antibody affinity by SPR; internalization assays; and in vivo syngeneic / xenograft disease models. Book a meeting now, link in the comments section.   #ISSX2024 #CRDMO #DMPK #ISSX2022 #DiscoveryServices

📌 Join Us at Global Bio-India 2024! 🌟   Syngene is excited to participate in Global Bio-India 2024 at Pragati Maidan, New Delhi, from September 12 to 14, 2024.   We’re driving innovation to support both large and small biopharma companies, as well as academic institutions in India and globally. Discover how our advanced solutions can accelerate your drug discovery, development, and manufacturing processes, across biologics and small molecules.   Book your meeting now! 👉 Link in comments.   See you there! #Innovation #BioPharma #GlobalBioIndia2024 #Syngene   

Syngene’s Annual Operational Excellence Certification Ceremony was a special occasion to celebrate our unwavering commitment to operational excellence and honor those who have made significant strides in various key programs of Operational Excellence, including Black Belt, Green Belt, Kaizen, and continuous improvement. Our teams’ dedication has led to both internal achievements and significant industry recognition at national and global level.   Kiran Mazumdar Shaw was the guest of honor at the event and her presence underscored the significance of our commitment to operational excellence. Our MD & CEO, Jonathan Hunt was also present, along with CHRO, Andrew Webster, Executive Director and CFO, Sibaji Biswas and Senior Vice President, Discovery Services, Kenneth Barr, Ph.D. Alex Del Priore Alok Mehrotra Gresh Kumar   #OperationalExcellence #Syngene #SixSigma #ContinuousImprovement

We are excited to attend the Biologics Contract Manufacturing Asia 2024 event from 10-11 September, 2024 at Suntec Singapore Convention & Exhibition Centre. Meet us at Booth #40 to find out how Syngene can assist you in accelerating your R&D programs across Biologics.   To book a meeting, visit https://lnkd.in/gggqFPC6   Biologics is one of our core service offerings, encompassing mammalian and microbial systems, and providing integrated services throughout the drug discovery, development, and manufacturing process. As an industry leader with 30 years of experience, our solutions extend from discovery, development to analytical, viral testing, and custom biomanufacturing for clinical and commercial supplies.   We provide an end-to-end integrated offering, spanning Discovery, Development, and Commercial Manufacturing. Our facilities hold approvals from USFDA (with Zero 483 observations), EMA, and MHRA, along with certifications in GLP, GMP, and ISO standards. Recently, we have expanded our capabilities to include a Single-Use Bioreactor (SUB) capacity of 20KL, expandable to an additional 20KL, and a sterile fill-finish capacity of 1 million vials per day (comprising vials and PFS).   Our platform services encompass process development and intensified biomanufacturing, achieving industry-leading titres. Our expertise encompasses a wide range of biologics, including monoclonal antibodies, bispecific antibodies, antibody fragments, recombinant proteins, glycoproteins, mRNA, and microbial (E. coli and Pichia).   #Biologics #CRDMO #Syngene

We are excited to attend the Eurotox 2024 from 8-11 September, 2024 in Copenhagen, Denmark. Meet with our experts Achintya Das, Anwesha Anindita and Deepa V PhD,DABT. to discuss how Syngene can help you accelerate your drug discovery programs. To book a meeting, visit the link in the comments section.   ⏩ Our end-to-end Safety solutions • Full range of in silico, genotoxicity, in vitro and in-vivo (rodents and non-rodents) toxicology testing services across pharmaceuticals, vaccines, medical devices, agrochemicals, cosmetics, nutraceuticals etc. • Over 500 in-vivo and over 750 in-vitro Tox studies completed in the last five years and submitted to FDA/ EMA/ MHRA/ TGA/ PMDA and other global regulatory agencies by clients. • 13+ comprehensive IND-enabling tox packages delivered in the last five years to US/Europe/Japanese clients • OECD and ICH guidelines-compliant clinical pathology and histopathology services • Aperio GT-450 digital pathology system for automated scanning of histopathology slides • In-house SEND capabilities fully compliant with US-FDA requirements • Computational toxicology with DEREK Nexus® (Lhasa, UK) and CaseUltra® (MultiCase, USA) modeling tools to deliver fast in silico toxicity predictions • AAALAC-accredited, GLP-certified, ISO/IEC 17025-accredited facility for exploratory and GLP toxicology studies • Highly experienced and passionate team of scientists including 8 DABTs, 2 ERTs and 4 Board certified pathologists ⏩ Best-in-class speed and TAT • Fastest industry project initiation turn-around-time (TAT) for non-GLP and GLP rodent toxicology studies (2 to 3 weeks from compound receipt) • Fastest TAT in the industry for GLP pivotal 4-week rat toxicity studies (12 weeks) • Rapid TAT for exploratory 2-week rat toxicity study; pathology results within four weeks from the day of necropsy • Twenty-six week TAT for IND-enabling GLP safety tox package. #Eurotox2024 #Drugdiscovery #Syngene

📌 Syngene’s ESG Milestones: Driving Sustainable Growth 🌍💡 Reflecting our commitment to embedding sustainable and responsible practices throughout our operations, Syngene’s FY 2024 ESG Report provides an in-depth look into our progress on our sustainability journey.   💠Environment Highlights:  •82% increase in renewable energy use  •Maintained ‘Zero Waste to Landfill’ with 96% waste recycling  •42% of water recycled and reused  •Zero-water discharge policy across our Bangalore and Mangalore campuses  •Committed to Science Based Targets initiative (SBTi)   💠 Social Highlights:  •26% of workforce are women  •50% women representation on the Board of Directors  •Work-related injury rate of 0.03  •Rs 104 Mn Invested in CSR programs to benefit the community   💠Governance Highlights:  •Completed 87 audits with zero data breaches  •Assessed 132 Tier 1 suppliers on ESG criteria Notably, Syngene was recognized as one of India’s best-managed companies by Deloitte and honoured as a champion by the Institute of Supply Chain Management (ISCM) at the Pharma Supply Chain Management 5.0 Summit. Read the full report 👉 https://lnkd.in/du3zvp9T

Curious about what’s in store at our first European Syn-posium, Nordics Discovery, happening next week at the BioInnovation Institute, Copenhagen? Check out the agenda for insightful sessions by our industry experts Ralf Guenther and Miquel Salvà, along with networking opportunities, refreshments, and more!   Don’t miss this opportunity to dive into the latest in preclinical research and drug discovery. Register today to secure your spot! (Link in comments)   Medicon Valley Alliance   #NordicsDiscovery #SyngeneDrugDiscovery #DMPK #Biotherapeutics

Watch our ED and CFO, Sibaji Biswas, discuss #Syngene's growth prospects and the evolving landscape in the CRDMO space on CNBC-TV18's Half Time Report with Ekta Batra. During the discussion, Sibaji highlighted India's readiness to seize new opportunities, driven by its talent, scalable infrastructure, and available capital. Vishal Manchanda, pharma analyst from Systematix, also expressed strong optimism about Indian CDMOs, noting Syngene's comprehensive value chain as a significant advantage. #CRDMO #CNBC #Biopharma

Join us at the European Biomanufacturing Summit from September 10-11, 2024, in Berlin, Germany. Meet with Jeff Wong and Dr. Anne Bouchet at booth #14 to discuss how Syngene can accelerate your R&D programs across biologics. We offer end-to-end integrated biologics solutions, covering discovery, development, and commercial manufacturing. Our facilities, approved by the US FDA (zero 483 observations), EMA, and MHRA, provide flexible scalability for clinical and commercial manufacturing. We also offer a sterile fill-finish capacity of 1 million vials per day, including vials and pre-filled syringes (PFS). Our expertise spans various modalities, including monoclonal antibodies, bispecific antibodies, antibody fragments, recombinant proteins, glycoproteins, mRNA, and expression systems such as mammalian and microbial systems, including E. coli and Pichia. 👉 To book a meeting, write to us at [email protected] Looking forward to connecting with you in Berlin! #SyngeneBiologics #Biopharma #CDMO #EuropeanBiomanufacturingSummit2024